NCT06944522: An ongoing trial by BlueRock Therapeutics
This trial is ongoing. It must report results 2 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06944522 |
|---|---|
| Title | exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 17, 2025 |
| Completion date | March 31, 2027 |
| Required reporting date | March 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |